Tests a bone-strengthening device to prevent repeat hip fractures in women

Trial details

Who runs it

AgNovos Healthcare, LLC

Trial code

NCT04796350

Record updated

13 May 2026

Original description

A randomized controlled trial to evaluate AGN1 to prevent secondary hip fractures in osteoporotic women undergoing treatment of index hip fractures. Up to 2400 subjects will be randomized between a treatment group and a control group. Subjects will be followed for a minimum of 5 years after undergoing hip fracture repair surgery.Read full original descriptionShow less

Randomized Controlled Study of a Local Osteo-Enhancement Procedure (LOEP) to Prevent Secondary Hip Fractures in Osteoporotic Women Undergoing Treatment of Index Hip Fractures

A randomized controlled trial to evaluate AGN1 to prevent secondary hip fractures in osteoporotic women undergoing treatment of index hip fractures. Up to 2400 subjects will be randomized between a treatment group and a control group. Subjects will be followed for a minimum of 5 years after undergoing hip fracture repair surgery.

Inclusion: Subject is a postmenopausal female at least 1-year post menses and at least 65 years of age and less than 92 years of age; Subject presents with a low-energy index fragility hip fracture in one hip and will undergo surgical repair of the fractured hip; Subject has at least one of the following additional risk factors for a secondary hip fracture (as determined by subject or legally authorized representative (LAR) interview or medical record review):; Documented falls assessment indicating subject is at moderate or high risk of falls; Falls history (2 or more falls in the previous 12 months); History of vertigo, dizziness, or postural hypotension; Documented T-score < -2.5 at the hip; Taking more than 3 daily prescription medications; Visual impairment as confirmed by one of the following:; Subject reports difficulty seeing; Lack of depth perception or vision loss in one eye; Macular degeneration; Cataracts; Prior non-hip fragility fracture; Cognitive frailty as assessed by SPMSQ (mild cognitive impairment determined by SPMSQ ≤ to 4) or delirium; Parkinson's disease stage 3 or 4; 10-year hip fracture probability >15% using the FRAX® Fracture Risk Assessment Tool of the clinical site country; Subject is expected to be ambulatory after the hip fracture repair procedure. "Ambulatory" is defined as a patient's ability to ambulate beyond simple transfers with or without assistive devices; Informed consent is provided by the subject or the subject's LAR. Use of an LAR to obtain patient consent requires that the patient must understand and be able to participate in post operative restrictions and requirements; The subject's willingness, ability, and commitment to participate in screening, treatment, and all follow-up evaluations for the full duration of the study has been documented.

Exclusion: Subject has a history of hip surgery or previous hip fracture on the target unfractured hip contralateral to the index hip fracture; Subject has a progressive increase in undiagnosed pain in the target hip contralateral to the index fractured hip over the previous 3 months that in the opinion of the Investigator may suggest underlying bone or joint pathology on the unfractured side; Subject has an infection at the LOEP intended treatment site or has non-intact skin or acute traumatic injuries with open wounds close to the area of intended LOEP treatment; Subject has a history of metabolic bone disease other than osteoporosis (e.g., Paget's disease, renal osteodystrophy, or osteomalacia); Subject has active cancer; Subject has moderate or severe cognitive impairment as assessed by an SPMSQ of 5 or higher; In the judgement of the Investigator, the subject is not a good study candidate (e.g., poor mental health, or active drug or alcohol abuse issues), and or subject would not be a good candidate to undergo an ELECTIVE orthopedic surgical procedure such as a total hip arthroplasty in her current medical, physiological condition; Subject has end stage renal insufficiency defined as an estimated glomerular filtration rate (eGFR) < 15 mL/min; Subject has known allergies to calcium-based bone void fillers; Criterion omitted; Criterion omitted; Subject is currently enrolled in another interventional clinical study affecting the target hip; Subject has new fractures in addition to the index hip fracture at admission that, in the opinion of the investigator, would further compromise patient mobility, rehabilitation, or recovery; Subject has radiological evidence of gross bony or joint pathology of the hip, including signs predictive of atypical femoral fractures (e.g. cortical beaking), or has been diagnosed and/or treated for atypical femoral fractures; Criterion omitted; Criterion omitted; Criterion omitted; Criterion omitted; Criterion omitted; Criterion omitted; Criterion omitted; Criterion omitted; Criterion omitted; Subject fails pre-operative or intraoperative eligibility criteria as specified in section 7.4.2. of the clinical investigation plan.

ClinicalTrials.gov NCT04796350